Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study

por Hong, D S, Bauer, T M, Lee, J J, Dowlati, A, Brose, M S, Farago, A F, Taylor, M, Shaw, A T, Montez, S, Meric-Bernstam, F, Smith, S, Tuch, B B, Ebata, K, Cruickshank, S, Cox, M C, Burris, H A, Doebele, R C
Publicado 2019

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma

por Schlumberger, M, Elisei, R, Müller, S, Schöffski, P, Brose, M, Shah, M, Licitra, L, Krajewska, J, Kreissl, M C, Niederle, B, Cohen, E E W, Wirth, L, Ali, H, Clary, D O, Yaron, Y, Mangeshkar, M, Ball, D, Nelkin, B, Sherman, S
Publicado 2017